Research programme: peptidomimetic therapeutics - Ra Pharmaceuticals/Merck
Latest Information Update: 28 Dec 2021
At a glance
- Originator Merck & Co; Ra Pharmaceuticals
- Class Cardiovascular therapies; Cyclic peptides; Peptidomimetics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders